USD10
OMER Shares
About OmerosOmeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
USD10
OMER Shares
About OmerosOmeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 27 at 1:30 PM GMT+0
MARKET CAP
$700.50M
OPEN PRICE
$10.40
LOW (1Y)
$2.95
HIGH (1Y)
$17.65
LOW (24H)
$9.86
HIGH (24H)
$10.41
VOLUME (24H)
$876.22K
56.48%
Price history
Time | Price | Change |
|---|---|---|
Today | $10.40 | |
1 Day | $10.31 | |
1 Week | $11.02 | |
1 Month | $11.95 | |
1 Year | $8.47 |